Viral Hepatitis Situational Analysis
2021
Policy landscape analysis for DOH & WHO


Our clients—across pharma, global health agencies, and government—trust us because we don’t just deliver reports; we deliver results they can stand behind.
We are proud to have earned the continued confidence of multinational companies, development partners, and national health institutions, with repeat engagements and consistently high satisfaction across projects. Whether it’s guiding an HTA submission, quantifying health impact, or shaping national policy, we partner with our clients to drive outcomes that matter.

We specialize in end-to-end HTA support, helping private sector innovators succeed within the Philippine HTA system. From prioritization to dossier development and engagement with the HTA Council, we build submissions that are scientifically rigorous, locally grounded, and stakeholder-ready.
What our clients value: Clear guidance, deep understanding of HTA Philippines, and submissions that gain traction with decision-makers.

From costing and economic modeling to equity analysis and global health training, our HEOR work informs policy, guides investments, and supports better health system decisions. We are proud to be a trusted partner of WHO, UNICEF, academic leaders, and regional health institutions.
What our clients value: Contextualized insights, technical rigor, and deliverables that translate directly into policy action.




2021
Policy landscape analysis for DOH & WHO
2021
National market assessment with FIND
2022
HTA + BIA of a novel biologic treatment
2022
Coverage and pricing impact analysis
2023
Cost structure design for UNICEF and DOH
2022–2025
Capacity building with Univ. of Washington
2024
COI and BOD study on obesity burden
2024
Evaluation of equity-focused HE methods in Zamboanga
100% of projects completed on time, meeting or exceeding stakeholder expectations
Multiple repeat engagements from multinational pharma and international agencies
High satisfaction ratings from both public and private clients
Outputs consistently validated by KOLs, HTA Council reviewers, and academic peers



DELOS TRINOS, JOHN PAUL R.
DELOS TRINOS, JOHN PAUL R.
Leong, R. N., delos Trinos, J. R., Gerodias, F., Mojica, V. J., Alconera, C. J., Tamayo, R. L., Alacapa, J., Almirol, B. J., Paredes, K. P., Lim, S., & Tumanan-Mendoza, B. (2023). Budget impact analysis of utilization of Sacubitril/Valsartan for the treatment of heart failure with reduced ejection fraction in the Philippines. Value in Health Regional Issues, 36, 105–116. https://doi.org/10.1016/j.vhri.2023.02.009 (Corresponding author)
DELOS TRINOS, JOHN PAUL R.
Academic Qualifications
Professional Training and Specialized Courses
Focused on incorporating equity considerations into cost-effectiveness analysis to inform policy decisions.
Provided in-depth training on methodological advancements in economic evaluation for health technology assessment and policy decision-making.
LEONG, ROBERT NEIL F.
LEONG, ROBERT NEIL F.
Academic Qualifications
Bionote
Robert is an internationally trained biostatistician, mathematical epidemiologist, and economic evaluation specialist with extensive experience in health data analytics, health economics, and mathematical modeling. He is the Chief Data Officer of metaHealth Insights and Innovations, Inc., leading health technology assessments (HTAs) to support evidence-based decision-making for healthcare interventions.
Robert’s expertise in vaccine economics, biostatistics, and health modeling has been duly recognized with his appointment as a voting member of the inaugural Philippine National Immunization Technical Advisory Group (2024–present), where he chairs the Health Economics subcommittee, providing strategic guidance on the cost-effectiveness and programmatic implications of immunization policies.
He has been involved in economic evaluations of vaccines, including rotavirus and pneumococcal vaccines, supporting their inclusion in National Immunization Programs in the United States and Australia. In the Philippines, his work has also guided the inclusion of cardio- and immunotherapeutic medicines in the Philippine National Formulary, ensuring equitable access to essential treatments.
Robert holds a PhD from UNSW Sydney, Australia. He is an active member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Philippine Statistical Association Inc. (PSAI), the American Statistical Association (ASA), and the International Statistics Institute (ISI).
ALACAPA, JASON V.
ALACAPA, JASON V.
Wong, J. Q., Co, S. A. L., Haw, N. J. L., Cortez, J. F., Bagas, J., Reyes, M. S. G., Lim, H. P. M., Fowler, K. C., & Alacapa, J. V. (2015). Colorectal cancer screening in the Philippines: A cost-utility analysis. Philippine Health Insurance Corporation (PhilHealth). https://www.philhealth.gov.ph/about_us/studies/abstract/14.ColorectalCancerScreening2015.pdf
ALACAPA, JASON V.
Academic Qualifications
Professional Training and Specialized Courses